Zacks Bull and Bear of the Day Highlights: CONSOL Energy, Navigant Consulting, CV...

Zacks Bull and Bear of the Day Highlights: CONSOL Energy, Navigant Consulting, CV Therapeutics, Conseco and Centennial Communications

CHICAGO--(Business Wire)--
Zacks Equity Research highlights CONSOL Energy, Inc. (NYSE: CNX)
as the Bull of the Day and Navigant Consulting (NYSE: NCI) as the Bear
of the Day. In addition, Zacks Equity Research provides analysis on CV
Therapeutics (Nasdaq: CVTX), Conseco, Inc. (NYSE: CNO) and Centennial
Communications (Nasdaq: CYCL).

Full analysis of all these stocks is available at
http://at.zacks.com/?id=2676.

Here is a synopsis of all five stocks:

Bull of the Day: CONSOL Energy, Inc. (NYSE: CNX)

We are upgrading our recommendation of CONSOL Energy to Buy from
Hold and raising our target price to $107.00 per share up from $86.00
per share given the strong domestic and export coal fundamentals as
well as the recent 33% pullback in the company's stock price in the
last three weeks. With both volumes and average price realizations
looking to increase substantially through 2010, CNX should be able to
grow its 2010 earnings more than 3.5x our 2008 estimate.

Bear of the Day: Navigant Consulting (NYSE: NCI)

Shares of Navigant Consulting are trading at 19.9x and 17.4x our
2008 and 2009 EPS estimates, respectively, and at an 9% and 19%
premium to the peer group average, respectively. On the second quarter
earnings call, management effectively lowered its full-year outlook
for operations in the core business.

Until we see further evidence that NCI's business has fully
recovered from the issues that plagued company throughout much of
2007, we do not believe that a premium valuation, relative to the peer
group, is warranted. Our price target reflects of multiple of 15x our
2008 EPS estimate.

Latest Posts on the Zacks Analyst Blog:

CV Therapeutics (Nasdaq: CVTX)

Several big regulatory decisions will make 2008 a pivotal year for
CV Therapeutics Inc. The first positive one came in April with the
approval of Lexiscan for myocardial perfusion imaging. In July, the
European Medicines Agency approved its chronic angina drug Ranexa in
Europe. However, the biggest decisions are still to come.

The Street is pretty split on CVTX right now. We are in the
moderately positive camp, believing that Ranexa will eventually pick
up steam after the label expansion(s). We remind investors, there are
three separate applications here: one for first-line angina, one for a
potential anti-arrhythmic claim, and another for use in diabetics with
coronary disease.

Conseco, Inc. (NYSE: CNO)

Conseco is expected to release its 2Q08 financial results between
August 6 and August 16, 2008. The first quarter operating earnings
came in at $0.11 per share, much weaker than the estimates, though
better than the results of the past few quarters.

We are a bit disappointed with the lower-than-expected results
1Q08 results. While Bankers Life and Colonial Penn segments continued
with steady growth and Conseco Insurance Group turned profitable, the
losses in the Runoff segment were not preventable. Though management
expects better results in future, we remain concerned with the
continued weakness in the results for the past few quarters.

Centennial Communications (Nasdaq: CYCL)

We are upgrading our recommendation to Hold for Centennial
Communications Corp., a regional provider of wireless and integrated
communications, based on the company's recent operational performance,
along with sustainable subscriber growth across all of its operational
areas.

CYCL delivered better-than-expected operating results in the most
recent quarter, beating our expectations with revenues and customer
growth across all its business areas. Importantly, the annual
consolidated revenues of approximately $1 billion and $400 million in
adjusted operating income for fiscal year 2008 represents a first time
operational achievement for the company. CYCL continues to grow its
U.S. wireless business with total revenues of $550.7 million for
fiscal year 2008.

Get the most recent insight from Zacks Equity Research with the
free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks
that are likely to outperform (Bull) or underperform (Bear) the
markets over the next 3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides
analysis from Zacks Equity Research about the latest news and events
impacting stocks and the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and
qualitative analysis to help investors know what stocks to buy and
which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives them
keen insights to developments that affect company profits and stock
performance. Recommendations and target prices are six-month time
horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights
of the latest analysis from Zacks Equity Research. Subscribe to this
free newsletter today by visiting http://at.zacks.com/?id=2677.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which
was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew
he could find patterns in stock market data that would lead to
superior investment results. Amongst his many accomplishments was the
formation of his proprietary stock picking system; the Zacks Rank,
which continues to outperform the market by nearly a 3 to 1 margin.
The best way to unlock the profitable stock recommendations and market
insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your
free subscription to Profit from the Pros at
http://at.zacks.com/?id=4582.

Visit http://www.zacks.com/performance for information about the
performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results.
Investors should always research companies and securities before
making any investments. Nothing herein should be construed as an offer
or solicitation to buy or sell any security.

Zacks.com
Mark Vickery
312-265-9380
Visit: www.zacks.com

Copyright Business Wire 2008